Cardiomyopathy, Hypertrophic clinical trials

The registry lists 363 studies for Cardiomyopathy, Hypertrophic across more than 10 countries. 116 are recruiting or about to start. 303 of them are mainly about Cardiomyopathy, Hypertrophic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Get an email when these change. Save the Cardiomyopathy, Hypertrophic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 138
Recruiting: 81
Status unknown: 46
Active, not recruiting: 40
Not yet recruiting: 24
Terminated: 17

Phase

Phase 2: 45
Phase 3: 28
Phase 1: 20
Phase 4: 16
Early Phase 1: 2

Where

United States: 125
China: 71
United Kingdom: 51
France: 32
Italy: 30
Germany: 28

Who runs them

Bristol-Myers Squibb (26) · National Heart, Lung, and Blood Institute (NHLBI) (24) · Xijing Hospital (11) · China National Center for Cardiovascular Diseases (9) · Cytokinetics (7) · Shandong Suncadia Medicine Co., Ltd. (7) · Meshalkin Research Institute of Pathology of Circulation (6) · Mayo Clinic (6)

What is being tested here

Drugs under test in Cardiomyopathy, Hypertrophic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
MYK-461	3	7	19
Aficamten	2	5	9
HRS-1893	1	1	7
Empagliflozin	1	1	2
Naproxen	1	0	1
Pregabalin	1	0	1
Henagliflozin	1	0	1
Ninerafaxstat	1	0	1
Verapamil	1	0	1
Bisoprolol	1	0	1

Drug classes tested here SGLT2 inhibitors 2 open · Calcium channel blockers 1 open · Beta blockers 1 open · Angiotensin receptor blockers (ARBs) 7

Coming up

11phase 3 studies under way

40studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Jan 2027A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy · Phase 3 · Lexicon Pharmaceuticals
Nov 2026The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction · Second Affiliated Hospital, Zhejiang University, School of Medicine
Nov 2026ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy · Yonsei University
Nov 2026A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy · Bristol-Myers Squibb
Dec 2026IMPACT-CMH: Impact of Mitral Valve and Subvalvular Abnormalities in Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten · French Cardiology Society
Dec 2026A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy · Imbria Pharmaceuticals, Inc.
Dec 2026The Application of T1 Mapping in Real-World · Chinese Academy of Medical Sciences, Fuwai Hospital
Dec 2026Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US · Bristol-Myers Squibb
Dec 2026A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease · McGill University Health Centre/Research Institute of the McGill University Health Centre
Dec 2026REFINE-HCM: Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy · SuZhou Sinus Medical Technologies Co.,Ltd

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger. 21 (26%) take children under 18. 1 (1%) are for women only and 1 (1%) for men only; 13 (16%) take healthy volunteers.

Recruiting studies that take each age, of 81
Age	Women	Men
10	15 (19%)	16 (20%)
18	72 (89%)	72 (89%)
30	76 (94%)	76 (94%)
40	78 (96%)	78 (96%)
50	79 (98%)	79 (98%)
65	79 (98%)	79 (98%)
75	76 (94%)	76 (94%)
85	64 (79%)	64 (79%)

Across all 363 studies, recruiting or not: 22% stop at 75 or younger and 13% at 65; 24% take children; <1% are for women only and 1% for men only; 17% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Cardiomyopathy, Hypertrophic studies take

Of 20 phase 2 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 36 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	5 mo3–12 · 12 studies	—	—
Phase 2	36 mo15–43 · 20 studies	—	—
Phase 3	21 mo19–36 · 15 studies	—	—
Interventional, no phase	52 mo26–60 · 52 studies	—	43 mo26–60 · 47 studies
Observational	85 mo43–… · 82 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Newly registered1

Focal Pulsed Field Ablation of Ventricular TachycardiaNov 10, 2026NCT07929545

Studies

Recruiting first, then most recently updated. Showing 50 of 363. Browse all 363 → or search them.